Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma. (PREDICTUMAB)
Primary Purpose
Severe Asthma
Status
Recruiting
Phase
Phase 4
Locations
Belgium
Study Type
Interventional
Intervention
Randomisation to omalizumab
Randomisation to mepolizumab
Sponsored by
About this trial
This is an interventional treatment trial for Severe Asthma
Eligibility Criteria
Inclusion Criteria: • Signed informed consent form (ICF),
- Age >18+ years at time of signing ICF,
- Able to comply with the study protocol, in the investigator's judgment,
- Documented physician-diagnosed asthma ,
- Patients with severe disease and eligible to omalizumab and mepolizumab, and who have not yet received any of these therapies.
Exclusion Criteria:
- History of evidence of drug/substance abuse that would pose a risk to patient safety, interfere with the conduct of study, have an impact on the study results, or affect the patient's ability to participate in the study, in the opinion of the investigator
- Treatment with any investigational therapy within 6 months or 5 drug half-lives prior to enrolment.
- Known sensitivity to any of the active substances or their excipients to be administered during the study.
Sites / Locations
- Universitair Ziekenhuis Brussel
- CHU de Charleroi
- Grand Hôpital de Charleroi
- Katholieke Universiteit Leuven
- AZ Delta Roeselare
- Cliniques universitaires St-LucRecruiting
- Centre Hospitalier Universitaire Saint Pierre
- Brugmann University Hospital
- Erasme University Hospital
- University Hospital, Ghent
- University Hospital of Liege
- CHR Namur
- Centre Hospitalier Universitaire Dinant Godinne - UCL Namur
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Omalizumab
Mepolizumab
Arm Description
Patients randomized to omalizumab and then prolonged or not (based on their response at 4 months) until the end of the study (22mo). Non responders will be switched to mepolizumab arm.
Patients randomized to mepolizumab and then prolonged or not (based on their response at 6 months) until the end of the study (22mo). Non responders will be switched to omalizumab arm.
Outcomes
Primary Outcome Measures
Efficacy on asthma symptoms
Asthma Control Test: 5 items of score 1 to 5 about symptoms, with result of 20 or above indicates good control; 15 to 19 indicates no good control and below 15 indicates no control at all, and a change of 3 points considered as clinically significant.
Efficacy on lung function
Lung function measured as forced expiratory volume in one sec (FEV1), % predicted value (normal value of 80% predicted or above, and change of 100 mL considered as clinically significant).
Efficacy on severe exacerbations
Number of exacerbation(s) per period of time (corrected per year) requiring systemic corticosteroid treatment for at least 3 days, and/or emergency visit or hospitalization for acute asthma.
Secondary Outcome Measures
Predictive factors of therapeutic response
The putative predictive factors of therapeutic response to omalizumab or mepolizumab which will be assayed are the following: age at onset, year (> or < 30yrs); presence of nasal polyps, Y/N; blood eosinophils, n/microliter (< or > 300/microl); serum total IgE, units/L; serum periostin, ng/ml. A proteomic analysis will also be carried out on plasma samples.
Full Information
NCT ID
NCT03476109
First Posted
October 17, 2017
Last Updated
October 26, 2022
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Collaborators
University Hospital, Ghent, University of Liege, CHU de Charleroi, Erasme University Hospital, Centre Hospitalier Universitaire UCLouvain Namur, Universitair Ziekenhuis Brussel, Brugmann University Hospital, Grand Hôpital de Charleroi, AZ Delta, Centre Hospitalier Universitaire Saint Pierre, KU Leuven
1. Study Identification
Unique Protocol Identification Number
NCT03476109
Brief Title
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
Acronym
PREDICTUMAB
Official Title
Predictive Factors and Magnitude of Response to Omalizumab and Mepolizumab in Allergic and Eosinophilic Severe Asthma: a Pragmatic Multicenter Trial in Belgium.
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 10, 2019 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Collaborators
University Hospital, Ghent, University of Liege, CHU de Charleroi, Erasme University Hospital, Centre Hospitalier Universitaire UCLouvain Namur, Universitair Ziekenhuis Brussel, Brugmann University Hospital, Grand Hôpital de Charleroi, AZ Delta, Centre Hospitalier Universitaire Saint Pierre, KU Leuven
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Pragmatic trial to define the magnitude and the predictive factors of the response to omalizumab and mepolizumab in adult patients with severe refractory asthma and eligible to both therapies.
Detailed Description
Title "PREDICTUMAB: Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: a multicenter, open, active-controlled, randomized trial in adult patients in Belgium".
Rationale and background New treatments are now available to treat severe refractory asthma, which affects about 3 to 5% of asthma patients. In particular, biological therapies using monoclonal antibodies targeted to immunoglobulin E (IgE) or interleukin (IL)-5 (and in the future other cytokines or growth factors) benefit to certain patients. Identifying those patients who will better benefit from a specific treatment requires the validation of features (clinical traits, biomarkers) that are predictive of the therapeutic outcome. Such predictive strategy is not available to decide whether anti-IgE (omalizumab) or anti-IL-5 (mepolizumab) should be prioritized in patients who are eligible to both therapies. In addition, the comparison of the magnitude of the clinical benefits achieved by these therapies remains unexplored in this population.
Study Design
The study is designed to initially randomly allocate patients from two strata (with or without maintenance oral corticosteroids) to oma- vs mepolizumab. According to the evaluation of response (at 4 or 6 months, respectively), subjects will then be either prolonged (for 12 months, for both therapies) on the same therapy, or switched to the other. For those who were switched, treatment will be prolonged (or not, in dual failers) after 4 or 6 months according to their evaluation of response. Time-points for analysis will be at 4 or 6 months, 10 months (interim analysis) and 18 or 22 months (final, posttreatment analysis).
State-of-the-art
Asthma is one of the most frequent chronic diseases, affecting 5 to 10% of the population worldwide. Omalizumab and mepolizumab represent the approved antibodies that are indicated in allergic and eosinophilic phenotypes of severe asthma respectively. However, if some patients fall into only one phenotypic category based on these criteria, a substantial number of patients are potentially eligible to both therapies. In those patients, no information is available to orientate towards a preferable therapy as the predictive weight of additional phenotypic traits, such as associated nasal polyps or early- versus late onset of disease, remains unknown. In addition, no head-to-head comparison of these therapies is available in this population.
Objectives of the study
Primary objectives To determine clinical features and blood (or sputum) biomarkers able to predict a better response to omalizumab or mepolizumab in severe asthma patients eligible to both therapies.
To determine the magnitude of response, in terms of improvement in symptoms, exacerbation rate and/or lung function, in responders to omalizumab vs mepolizumab.
Secondary objectives To compare the global baseline characteristics (clinical and biological features) of patients responding to omalizumab vs mepolizumab.
Management and reporting of adverse events.
If during the study, an adverse event (AE) (serious or non-serious) is identified as attributed to omalizumab or mepolizumab, this will be documented as appropriate in routine good clinical practice, to the Federal Agency of Medicines and Products of Health (AFMPS) as well as to the Central Ethic Committee.
Confidentiality of data.
The identity and participation of subjects will remain strictly confidential, according to Belgian laws dated 8 Dec 1992 related to the protection of private life and dated 22 Aug 2002 related to patient rights.
Specimens and associated data will be labeled with unique patient identification number.
Data will be anonymized in all files, results and publications related to the study.
The promoter confirms to authorize the regulatory surveillance, examination and controls by competent authorities, by allowing direct access to database/files, and this in full respect of confidentiality.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Severe Asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Factorial Assignment
Model Description
Severe asthma patients who are eligible to both anti-IgE (omalizumab) and anti-IL-5 (mepolizumab) therapies, will be randomized to decide the first treatment to start. Patients will then be prolonged or switched to the other according to the clinical response. There will be 5 possibilities: oma(lizumab) group, mepo(lizumab) group, oma-mepo switch, mepo-oma switch, and oma/mepo failure.
Masking
Outcomes Assessor
Masking Description
The analysis of the response rate and magnitude, as well as of biomakers predicting the response, will be performed by an independent assessor and a biostatistician.
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Omalizumab
Arm Type
Active Comparator
Arm Description
Patients randomized to omalizumab and then prolonged or not (based on their response at 4 months) until the end of the study (22mo).
Non responders will be switched to mepolizumab arm.
Arm Title
Mepolizumab
Arm Type
Active Comparator
Arm Description
Patients randomized to mepolizumab and then prolonged or not (based on their response at 6 months) until the end of the study (22mo).
Non responders will be switched to omalizumab arm.
Intervention Type
Drug
Intervention Name(s)
Randomisation to omalizumab
Other Intervention Name(s)
Active-controlled
Intervention Description
The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
Intervention Type
Drug
Intervention Name(s)
Randomisation to mepolizumab
Other Intervention Name(s)
Active-controlled
Intervention Description
The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
Primary Outcome Measure Information:
Title
Efficacy on asthma symptoms
Description
Asthma Control Test: 5 items of score 1 to 5 about symptoms, with result of 20 or above indicates good control; 15 to 19 indicates no good control and below 15 indicates no control at all, and a change of 3 points considered as clinically significant.
Time Frame
Up to 22 months
Title
Efficacy on lung function
Description
Lung function measured as forced expiratory volume in one sec (FEV1), % predicted value (normal value of 80% predicted or above, and change of 100 mL considered as clinically significant).
Time Frame
Up to 22 months
Title
Efficacy on severe exacerbations
Description
Number of exacerbation(s) per period of time (corrected per year) requiring systemic corticosteroid treatment for at least 3 days, and/or emergency visit or hospitalization for acute asthma.
Time Frame
Up to 22 months
Secondary Outcome Measure Information:
Title
Predictive factors of therapeutic response
Description
The putative predictive factors of therapeutic response to omalizumab or mepolizumab which will be assayed are the following: age at onset, year (> or < 30yrs); presence of nasal polyps, Y/N; blood eosinophils, n/microliter (< or > 300/microl); serum total IgE, units/L; serum periostin, ng/ml. A proteomic analysis will also be carried out on plasma samples.
Time Frame
Baseline features (and according to response at 22 months)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • Signed informed consent form (ICF),
Age >18+ years at time of signing ICF,
Able to comply with the study protocol, in the investigator's judgment,
Documented physician-diagnosed asthma ,
Patients with severe disease and eligible to omalizumab and mepolizumab, and who have not yet received any of these therapies.
Exclusion Criteria:
History of evidence of drug/substance abuse that would pose a risk to patient safety, interfere with the conduct of study, have an impact on the study results, or affect the patient's ability to participate in the study, in the opinion of the investigator
Treatment with any investigational therapy within 6 months or 5 drug half-lives prior to enrolment.
Known sensitivity to any of the active substances or their excipients to be administered during the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Charles Pilette, MD PhD
Phone
003227642866
Ext
2866
Email
charles.pilette@uclouvain.be
First Name & Middle Initial & Last Name or Official Title & Degree
Irina KAIDALINA-MAMBOUR, Inf
Phone
003227642813
Ext
2813
Email
irina.kaidalina-mambour@uclouvain.be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Charles Pilette
Organizational Affiliation
Cliniques universitaires Saint-Luc
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universitair Ziekenhuis Brussel
City
Brussel
State/Province
Brussels
ZIP/Postal Code
1090
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shane Hanon, MD
Facility Name
CHU de Charleroi
City
Charleroi
State/Province
Hainaut
ZIP/Postal Code
6000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rudi Peche, MD
Facility Name
Grand Hôpital de Charleroi
City
Charleroi
State/Province
Hainaut
ZIP/Postal Code
6000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pol-Marie Mingeot, MD
Facility Name
Katholieke Universiteit Leuven
City
Leuven
State/Province
Vlaams Brabant
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lieven Dupont, MD, PhD
Facility Name
AZ Delta Roeselare
City
Roeselare
State/Province
West-vlaanderen
ZIP/Postal Code
8800
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ulriche Himpe, MD
Facility Name
Cliniques universitaires St-Luc
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pilette Charles, MD PhD
Phone
003227642866
Ext
2866
Email
charles.pilette@uclouvain.be
First Name & Middle Initial & Last Name & Degree
Irina Kaidalina-Mambour, Inf
Phone
003227642813
Ext
2813
Email
irina.kaidalina-mambour@uclouvain.be
Facility Name
Centre Hospitalier Universitaire Saint Pierre
City
Bruxelles
ZIP/Postal Code
1000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vincent Ninane, MD
Facility Name
Brugmann University Hospital
City
Bruxelles
ZIP/Postal Code
1020
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Olivier Michel, MD, PhD
Facility Name
Erasme University Hospital
City
Bruxelles
ZIP/Postal Code
1070
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alain Michils, MD
Facility Name
University Hospital, Ghent
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guy Brusselle, MD, PhD
Facility Name
University Hospital of Liege
City
Liège
ZIP/Postal Code
4000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florence Schleich, MD, PhD
Facility Name
CHR Namur
City
Namur
ZIP/Postal Code
5000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vincent Hers, MD
Facility Name
Centre Hospitalier Universitaire Dinant Godinne - UCL Namur
City
Namur
ZIP/Postal Code
5530
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Olivier Vandenplas, MD, PhD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
We'll reach out to this number within 24 hrs